Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus Therapeutics (NASDAQ:FOLD) Trading 6.1% Higher
07:52am, Sunday, 26'th Apr 2020
Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s stock price traded up 6.1% during trading on Friday . The company traded as high as $12.88 and last traded at $12.82, 4,106,425 shares changed hands during
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by BidaskClub
06:32am, Saturday, 25'th Apr 2020
BidaskClub upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a buy rating in a report released on Tuesday, BidAskClub reports. Other analysts have also issued reports about th
Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020
11:00am, Friday, 24'th Apr 2020
CRANBURY, N.J., April 24, 2020 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 7,.
Analysts Anticipate Amicus Therapeutics, Inc. (NASDAQ:FOLD) Will Announce Quarterly Sales of $57.21 Million
07:48am, Friday, 24'th Apr 2020
Wall Street analysts forecast that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will post $57.21 million in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Amic
Amicus Therapeutics to Announce First Quarter —…—… Financial Results on May 7, —…—…
12:00am, Friday, 24'th Apr 2020Russell Okung: BTC Is the “Best Way” to Empower People
07:00pm, Wednesday, 22'nd Apr 2020
NFL player Russell Okung believes that bitcoin can potentially revolutionize the future of finance, and he's excited about investing in it.
Zacks: Analysts Expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) Will Announce Earnings of -$0.28 Per Share
10:14am, Wednesday, 22'nd Apr 2020
Equities analysts predict that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will post earnings per share of ($0.28) for the current quarter, according to Zacks Investment Research. Five analysts have issue
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Margaret G. Mcglynn Sells 10,000 Shares
08:46am, Tuesday, 21'st Apr 2020
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Margaret G. Mcglynn sold 10,000 shares of the business’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $
Amicus Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating
12:00am, Monday, 20'th Apr 2020Assenagon Asset Management S.A. Purchases 553,971 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
09:50am, Sunday, 19'th Apr 2020
Assenagon Asset Management S.A. raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 76.1% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 1
Insider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells 20,000 Shares of Stock
09:18am, Sunday, 19'th Apr 2020
Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price o
Stocks With Rising Relative Price Strength: Amicus Therapeutics
07:00am, Friday, 17'th Apr 2020
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.
Stocks With Rising Relative Price Strength: Amicus Therapeutics
12:00am, Friday, 17'th Apr 2020Leaked: Samsung Galaxy Fold 2 Has a Missing Feature From Note 10
11:48am, Tuesday, 14'th Apr 2020
Leaked report said no S Pen included in the device.
